GlassScriptPhysician profile
Michele D Brown
NPI 1124024237
$3,056.60
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,676 · 2020: $361 · 2021: $327 · 2022: $693.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $854.39 | 2019-2022 | |
| Therapeuticsmd, INC. | $501.98 | 2019-2022 | |
| Pfizer INC. | $419.73 | 2019-2022 | |
| Astellas Pharma US INC | $275.26 | 2019-2022 | |
| Vertical Pharmaceuticals, LLC | $237.43 | 2019-2020 | |
| Urovant Sciences INC | $165.80 | 2021-2022 | |
| Allergan, INC. | $141.35 | 2019-2020 | |
| Exeltis, USA INC. | $91.26 | 2019-2022 | |
| Lupin INC. | $82.68 | 2019-2020 | |
| Millicent US INC | $67.68 | 2019-2020 | |
| Avion Pharmaceuticals | $65.20 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $58.69 | 2019 | |
| Mayne Pharma Commercial LLC | $40.08 | 2021-2022 | |
| Agile Therapeutics, INC. | $24.46 | 2022 | |
| Ascend Therapeutics US, LLC | $16.24 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $14.37 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.